Skip to main content

Articles

Breo Ellipta: A Fixed-Dose Combination Oral Inhaler Receives FDA Approval for Long-Term Maintenance Treatment of COPD

Invokana (Canagliflozin): First-in-Class SGLT2 Inhibitor Approved for the Treatment of Type 2 Diabetes

Highlights from the ADA President’s Research Sessions

Look AHEAD: Lifestyle Intervention Cost-Effective in Overweight Patients with Type 2 Diabetes

SGLT-2 Inhibitors Show Durability in Glycemic Control, Weight-Loss Maintenance

Pooled Analysis Confirms CV Benefits of DPP-4 Inhibition

Adding Linagliptin to Basal Insulin Reduces Hypoglycemia in Older Patients with Type 2 Diabetes

Novel Predictors of Outcomes in Diabetes

Reductions in HbA1c Levels, Hypoglycemia, and Weight with Linagliptin in Patients with Type 2 Diabetes and Renal Impairment

Lifestyle Intervention Beneficial in Patients with Diabetes, but Not for CV Parameters

Page 166 of 244
Results 1651 - 1660 of 2434